Poltreg SA is a Poland-based company engaged primarily in biotechnology and medical research. The Company conducts research in the field of autoimmunological diseases. The Company works on a method of healing, that uses t-regulated cells (TREGs). The Firm possesses its own, patented technology to obtain T-regulated lymphocytes, that are used in the therapy. The Company works on therapy for diseases such as type one diabetes, type two diabetes, and multiple sclerosis. In its research, the Company cooperates with multiple specialists from various fields of science. The Company is developing its own research center, which is intended as a basic location for conducting future research activities.

Employees

Sector

Biotechnology & Medical Research

Calendar

11-17 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
26-10-02	PLN 20.30	-0.49%	1,287
26-10-01	PLN 20.40	-0.49%	4,187
26-09-30	PLN 20.50	-1.91%	10,393
26-09-29	PLN 20.90	-3.69%	8,180
26-09-28	PLN 21.70	+1.88%	5,955

Delayed Quote Warsaw S.E.

More quotes

Quarterly revenue - Rate of surprise

Company calendar

Delayed Warsaw S.E. 11:55:44 2026-10-02 EDT			5-day change	1st Jan Change
20.30 ^PLN	-0.49%		-4.69%	-17.14%

09-09	Poltreg S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-11	Poltreg S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	120M 30.88M 27.44M 25.61M 23.34M 44.03M 2.97B 44.44M 310M 1.52B 116M 113M 4.87B	P/E 2024	-9.12x	P/E 2025	-4.39x
Enterprise Value	110M 28.27M 25.12M 23.44M 21.37M 40.3M 2.72B 40.68M 284M 1.39B 106M 104M 4.46B	EV / Sales 2024	380x	EV / Sales 2025	-
Free-Float	67.57%	Yield 2024 *	-	Yield 2025	-

09-09	Poltreg S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-11	Poltreg S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-05	Poltreg S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-10	PolTREG SA Moves Forward With European Registration Process For TREG Therapy In Type 1 Diabetes	CI
11-19	Poltreg S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-07	Immuthera and Its Wholly Owned Subsidiary of Poltreg S.A Appoints Adrian Bot to Its Board of Directors	CI
25-09-10	Poltreg S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-08-04	PolTREG S.A. Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007	CI
25-07-31	Poltreg and Immuthera Secure Positive FDA Opinion, Paving the Way for a Registrational Pre-Symptomatic Type 1 Diabetes Trial	CI
25-06-13	Poltreg Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy	CI
25-06-13	Poltreg Establishes U.S. Subsidiary Immuthera To Advance International Development Strategy	RE
25-05-15	PolTREG S.A. Announces Positive Ema Opinion on Pediatric Investigation Plan for PolTREG's Treg Therapy in Type 1 Diabetes	CI
25-05-14	Poltreg S.A. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI

03-10	PolTREG moves forward with the European registration process for TREG therapy in type 1 diabetes	GL
11-07	Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies	GL
25-08-04	PolTREG Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007	GL
25-07-31	PolTREG and U.S. Subsidiary Immuthera Secure Positive FDA Opinion, Paving the Way for a Registrational Pre-Symptomatic Type 1 Diabetes Trial	GL
25-07-04	Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions	GL

Poltreg S.A. Stock

Stocks

PTG

PLPLTRG00038

Biotechnology & Medical Research

Valuation: Poltreg S.A.

Chart: Poltreg S.A.

Latest news: Poltreg S.A.

Press Releases: Poltreg S.A.

News in other languages: Poltreg S.A.

Quotes and Performance

Price Extremes

Managers and Directors: Poltreg S.A.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

03-11	PolTREG poursuit la procédure d’enregistrement au niveau européen de sa thérapie à base de TREG destinée au traitement du diabète de type 1
03-11	PolTREG treibt das europäische Zulassungsverfahren für die TREG-Therapie bei Typ-1-Diabetes voran

1 day	-0.49%
1 week	-4.69%
Current month	-0.98%
1 month	-7.31%
3 months	+10.33%
6 months	+15.67%
Current year	-17.14%

1 week	19.6	21.6
1 month	19.1	23.4
Current year	16	28.6
1 year	16	29.8
3 years	16	60
5 years	16	73.9
10 years	16	73.9

Manager	Title	Age	Since
Piotr Trzonkowski CEO	Chief Executive Officer	-	2019-04-30
Marta Druch CTO	Chief Tech/Sci/R&D Officer	-	2021-10-31
Daniel Shelly PRN	Corporate Officer/Principal	-	2024-02-20

Director	Title	Age	Since
Marcin Jerzy Mierzwiñski CHM	Chairman	-	2021-05-23
Oktawian Zbigniew Jaworek BRD	Director/Board Member	51	2021-05-20
Wojciech Golak BRD	Director/Board Member	43	2023-05-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
POLTREG S.A.	-0.49%	-4.69%	-17.48%	-66.17%	30.88M
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.16B
ARGENX SE	-0.37%	-3.81%	+19.51%	+78.12%	57.39B
LONZA GROUP AG	+1.63%	-1.61%	+3.16%	+36.89%	47.64B
REVOLUTION MEDICINES, INC.	-0.69%	+1.15%	+338.09%	+707.84%	44.29B
IQVIA HOLDINGS INC.	+1.94%	-2.88%	+28.36%	+33.04%	42.5B
BEONE MEDICINES AG	+0.43%	-2.27%	+4.10%	+110.15%	40.71B
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+54.06%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	+1.56%	+4.53%	+31.34%	+26.92%	28.53B
BIONTECH SE	-0.11%	-2.55%	-8.18%	-12.10%	24.34B
Average	+0.72%	-0.53%	+45.76%	+106.29%	39.06B
Weighted average by Cap.	+1.15%	-0.84%	+57.00%	+134.70%

	2024	2025
Net sales	350K 90K 79.97K 74.64K 68.03K 128K 8.65M 129K 903K 4.42M 338K 331K 14.2M	-
Net income	-18.71M -4.81M -4.27M -3.99M -3.64M -6.86M -462M -6.92M -48.28M -236M -18.06M -17.67M -759M	-26M -6.69M -5.94M -5.54M -5.05M -9.53M -643M -9.62M -67.09M -329M -25.1M -24.56M -1.05B
Net Debt	-37.69M -9.69M -8.61M -8.04M -7.32M -13.81M -932M -13.94M -97.25M -476M -36.38M -35.59M -1.53B	-10.16M -2.61M -2.32M -2.17M -1.98M -3.73M -251M -3.76M -26.23M -128M -9.81M -9.6M -412M